Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

+0.31 (+3.26%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
320,561 shs
Average Volume
611,029 shs
Market Capitalization
$222.30 million
P/E Ratio
Dividend Yield
Price Target

Acrivon Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
105.1% Upside
$20.14 Price Target
Short Interest
4.43% of Float Sold Short
Dividend Strength
News Sentiment
0.87mentions of Acrivon Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth
From ($3.42) to ($3.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.15 out of 5 stars

Medical Sector

323rd out of 910 stocks

Pharmaceutical Preparations Industry

144th out of 426 stocks

ACRV stock logo

About Acrivon Therapeutics Stock (NASDAQ:ACRV)

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

ACRV Stock Price History

ACRV Stock News Headlines

Acrivon Therapeutics, Inc. (ACRV)
Putin and other countries have a plan
Did you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon.
Putin and other countries have a plan
Did you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon.
Acrivon Therapeutics: Q4 Earnings Insights
See More Headlines
Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$5.46 per share


Free Float
Market Cap
$222.30 million
Not Optionable
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Peter Blume-Jensen M.D. (Age 61)
    Ph.D., Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
    Comp: $1.01M
  • Ms. Kristina Masson M.B.A. (Age 43)
    Ph.D., Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director
  • Mr. Rasmus Holm-Jorgensen (Age 53)
    Chief Financial Officer
    Comp: $1M
  • Dr. Eric J. Devroe Ph.D. (Age 46)
    Chief Operating Officer
    Comp: $614.78k
  • Ms. Katharine Peterson CPA
    Vice President of Finance & Accounting
  • Dr. Adam D. Levy M.B.A.
    Ph.D., Senior VP and Head of Investor Relations & Corporate Affairs
  • Mr. Bruce Close
    Vice President of Quality & Compliance
  • Ms. Mary-Alice Miller J.D. (Age 50)
    Chief Legal Officer
  • Ms. Parvin Miah
    VP & Head of Human Resources
  • Dr. Erick Gamelin M.D. (Age 66)
    Ph.D., Chief Development Officer
    Comp: $480.72k

ACRV Stock Analysis - Frequently Asked Questions

Should I buy or sell Acrivon Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRV shares.
View ACRV analyst ratings
or view top-rated stocks.

What is Acrivon Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued 1-year target prices for Acrivon Therapeutics' shares. Their ACRV share price targets range from $14.00 to $26.00. On average, they expect the company's share price to reach $20.14 in the next twelve months. This suggests a possible upside of 105.1% from the stock's current price.
View analysts price targets for ACRV
or view top-rated stocks among Wall Street analysts.

How have ACRV shares performed in 2024?

Acrivon Therapeutics' stock was trading at $4.92 at the beginning of 2024. Since then, ACRV shares have increased by 99.6% and is now trading at $9.82.
View the best growth stocks for 2024 here

Are investors shorting Acrivon Therapeutics?

Acrivon Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 533,000 shares, an increase of 10.1% from the March 15th total of 484,000 shares. Based on an average trading volume of 661,100 shares, the days-to-cover ratio is presently 0.8 days. Approximately 4.4% of the shares of the stock are sold short.
View Acrivon Therapeutics' Short Interest

When is Acrivon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ACRV earnings forecast

How were Acrivon Therapeutics' earnings last quarter?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) released its quarterly earnings results on Thursday, March, 28th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.14.

What ETFs hold Acrivon Therapeutics' stock?

ETFs with the largest weight of Acrivon Therapeutics (NASDAQ:ACRV) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

When did Acrivon Therapeutics IPO?

Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of Acrivon Therapeutics?

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACRV) was last updated on 4/23/2024 by Staff

From Our Partners